Cyclerion Therapeutics Inc. – Material Contracts Watch

EX-10.30

from S-4/A 51 pages License Agreement

12/34/56

EX-10.20

from S-4/A 2 pages First Amendment to the Korsana Biosciences, Inc. 2025 Equity Incentive Plan

12/34/56

EX-10.34

from S-4/A 26 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type of Information That the Registrant Both Customarily and Actually Treats as Private and Confidential. Biologics Master Services Agreement

12/34/56

EX-10.33

from S-4/A 3 pages Amendment No. 1 to the Cell Line License Agreement

12/34/56

EX-10.32

from S-4/A 17 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type of Information That the Registrant Both Customarily and Actually Treats as Private and Confidential. Cell Line License Agreement

12/34/56

EX-10.31

from S-4/A 6 pages 1 Research Program

12/34/56

EX-10.30

from S-4/A 28 pages Platform Option Agreement

12/34/56

EX-10.28

from S-4/A 38 pages Antibody Discovery and Option Agreement

12/34/56

EX-10.32

from S-4 11 pages Korsana Biosciences, Inc. Warrant to Purchase Common Stock

12/34/56

EX-10.27

from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $330,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation

12/34/56

EX-10.26

from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $460,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation

12/34/56

EX-10.25

from S-4 10 pages 2. Base Salary. the Company Will Pay You an Initial Base Salary of $475,000 Per Year, Payable in Accordance With the Company’s Standard Payroll Schedule and Subject to Applicable Deductions and Withholdings. Your Base Salary Will Be Subject to Periodic Review and Potential Adjustment in the Company’s Discretion. Your Base Salary in Effect at Any Given Time Is Referred to Herein as the “Base Salary.” 3. Bonus Compensation

12/34/56

EX-10.24

from S-4 10 pages 1. Positions. as CEO, You Will Report to the Board, and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the CEO Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Will Not Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Expressly Authorized in Writing by the Board. Notwithstanding the Foregoing, You May Engage in Religious, Charitable and Other Community Activities So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company. 2. Compensation

12/34/56

EX-10.23

from S-4 13 pages Consulting Agreement

12/34/56

EX-10.22

from S-4 16 pages Indemnification Agreement

12/34/56

EX-10.21

from S-4 11 pages Korsana Biosciences, Inc. 2025equity Incentive Plan Stock Option Agreement [Incentive Stock Option // Nonstatutory Stock Option]

12/34/56

EX-10.20

from S-4 12 pages Korsana Biosciences, Inc. 2025 Equity Incentive Plan Restricted Stock Agreement

12/34/56

EX-10.19

from S-4 14 pages Korsana Biosciences, Inc. 2025 Equity Incentive Plan

12/34/56

EX-10.7

from 8-K 6 pages March 31, 2026 Regina Graul, PH.D. C/O *** Re: Amended and Restated Offer Letter Dear Regina

12/34/56

EX-10.6

from 8-K 23 pages Contingent Value Rights Agreement

12/34/56